Sage Therapeutics (FRA:SG7) Change In Payables And Accrued Expense : €-16.70 Mil (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Sage Therapeutics Change In Payables And Accrued Expense?

Sage Therapeutics's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was €-18.05 Mil. It means Sage Therapeutics's Accounts Payable & Accrued Expense declined by €18.05 Mil from Dec. 2023 to Mar. 2024 .

Sage Therapeutics's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was €-13.17 Mil. It means Sage Therapeutics's Accounts Payable & Accrued Expense declined by €13.17 Mil from Dec. 2022 to Dec. 2023 .

Sage Therapeutics Change In Payables And Accrued Expense Historical Data

The historical data trend for Sage Therapeutics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sage Therapeutics Change In Payables And Accrued Expense Chart

Sage Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

13.52

-35.90

16.33

12.32

-13.17

Sage Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-13.95	10.73	35.07	-44.46	-18.05

Sage Therapeutics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-16.70 Mil.

Sage Therapeutics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Sage Therapeutics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Sage Therapeutics (FRA:SG7) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sage Therapeutics Inc (FRA:SG7) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

SAGE:USA SG7:Germany

Address

215 First Street, Cambridge, MA, USA, 02142

Website

https://www.sagerx.com

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. The GABA receptor family, which is recognized as the inhibitory neurotransmitter in the CNS, mediates downstream neurologic and bodily function via activation of GABAA receptors. The NMDA-type receptors of the glutamate receptor system are a excitatory receptor system in the CNS. Dysfunction in these systems is implicated in a broad range of CNS disorders.

Sage Therapeutics (FRA:SG7) Headlines

No Headlines